Six published models, chosen by your answers the way the Dutch cardiovascular risk management guideline does it, plus the treatment effects from the trials. Every source is linked.
Treatment effects
The what-if sliders, all scopes
Lowering systolic blood pressure by 10 mmHg lowers the risk of major cardiovascular events by about 20 % (relative risk 0.80), across starting pressures. Lowering LDL cholesterol by 1 mmol/L lowers it by about 21 to 22 % (we use 0.79). Both come from meta-analyses of the randomised trials, and both are applied multiplicatively to the model's risk.
Source: Ettehad D et al. (Lancet 2016); Cholesterol Treatment Trialists' Collaboration (Lancet 2010). Blood pressure lowering for prevention of cardiovascular disease and death; Efficacy and safety of more intensive lowering of LDL cholesterol. The Lancet 387: 957-967; The Lancet 376: 1670-1681, 2016, 2010.
SMART-REACH
Lifetime, established vascular disease or diabetes
The lifetime companion of SMART, derived in the REACH registry of Western Europe and validated in North America and Utrecht. It estimates the years one can expect to live without a new heart attack or stroke, again with the competing chance of dying of something else. Treatment effects are applied the way the authors do it: as hazard ratios from the trials (a fifth less risk per 10 mmHg systolic, a fifth less per mmol/L LDL).
Source: Kaasenbrood L, Bhatt DL, Dorresteijn JAN et al.. Estimated life expectancy without recurrent cardiovascular events in patients with vascular disease: the SMART-REACH model. Journal of the American Heart Association 7(16): e009217, 2018.
LIFE-CVD
Lifetime, apparently healthy people
A lifetime model built in the Multi-Ethnic Study of Atherosclerosis, with two competing hazards: a heart attack or stroke, and death from another cause. Year by year up to age 90 it follows sex, blood pressure, non-HDL cholesterol, body mass index, smoking (now or before), diabetes and a parent with an early heart attack. It carries its own term for lowering LDL cholesterol; blood pressure, weight and smoking are changed in the profile itself.
Source: Jaspers NEM, Blaha MJ, Matsushita K et al.. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. European Heart Journal 41(11): 1190-1199, 2020.
SMART
Ten years, established vascular disease
For people who already had a heart attack, stroke, aneurysm or peripheral artery disease. Derived in the SMART cohort of Utrecht and in use in the ESC prevention toolbox. Inputs: age, sex, smoking, systolic blood pressure, diabetes, the locations of vascular disease, years since the first event, HDL and total cholesterol, kidney function and C-reactive protein.
Source: Dorresteijn JAN, Visseren FLJ, Wassink AMJ et al. (SMART Study Group). Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart 99(12): 866-872, 2013.
ADVANCE
Ten years, type 2 diabetes, no vascular disease
Derived in the ADVANCE trial of 7,168 people with type 2 diabetes. It predicts four-year risk from age at diagnosis, years of diabetes, sex, pulse pressure, treated hypertension, atrial fibrillation, retinopathy, HbA1c, the albumin/creatinine ratio and non-HDL cholesterol; we extend the four-year figure to ten years.
Source: Kengne AP, Patel A, Marre M et al. (ADVANCE Collaborative Group). Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. European Journal of Cardiovascular Prevention and Rehabilitation 18(3): 393-398, 2011.
Older adults (PROSPER)
Ten years, age 70 and over, no diabetes, no vascular disease
Above seventy the classic charts stop. This model was derived in the PROSPER trial of people aged 70 and older and takes competing risks into account: the chance of dying of something else first. It uses sex, age, smoking, systolic blood pressure, LDL and HDL cholesterol, kidney function (eGFR) and statin use.
Source: Stam-Slob MC, Visseren FLJ, Jukema JW et al.. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clinical Research in Cardiology 106: 58-68, 2017.
SCORE
Ten years, age 40 to 69, no diabetes, no vascular disease
The risk chart of the European Society of Cardiology, in its low-risk-country version (the Netherlands is one). From sex, age, smoking, systolic blood pressure and total cholesterol it reads the ten-year risk of dying of cardiovascular disease. As the Dutch guideline does, we multiply fatal risk by 3 for men and 4 for women to arrive at the risk of any heart attack or stroke, and by 1.5 for rheumatoid arthritis.
Source: Conroy RM, Pyörälä K, Fitzgerald AP et al. (SCORE project group). Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal 24(11): 987-1003, 2003.